Timothy J Wilkin, Barbara Taylor, Susan Olender, Scott M Hammer
{"title":"Advances in antiretroviral therapy.","authors":"Timothy J Wilkin, Barbara Taylor, Susan Olender, Scott M Hammer","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The 16th Conference on Retroviruses and Opportunistic Infections maintained its tradition of being recognized as the preeminent forum for detailing the state-of-the-art of antiretroviral therapy. Abundant new and updated information was presented on investigational drugs, approaches to the management of treatment-naive and -experienced patients, the use of drugs for prevention of mother-to-child HIV-1 transmission, and antiretroviral drug resistance. Of particular note were the continued advances in antiretroviral treatment and research emanating from resource-limited settings and the presentation of the results of 2 much-anticipated, phase III trials of interleukin-2, ESPRIT (Evaluation of Subcutaneous Proleukin in a Randomized International Trial) and SILCAAT (Subcutaneous, Recombinant Human Interleukin-2 in HIV-Infected Patients With Low CD4+ Counts Receiving Active Antiretroviral Therapy).</p>","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"17 2","pages":"68-88"},"PeriodicalIF":0.0000,"publicationDate":"2009-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Topics in HIV medicine : a publication of the International AIDS Society, USA","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The 16th Conference on Retroviruses and Opportunistic Infections maintained its tradition of being recognized as the preeminent forum for detailing the state-of-the-art of antiretroviral therapy. Abundant new and updated information was presented on investigational drugs, approaches to the management of treatment-naive and -experienced patients, the use of drugs for prevention of mother-to-child HIV-1 transmission, and antiretroviral drug resistance. Of particular note were the continued advances in antiretroviral treatment and research emanating from resource-limited settings and the presentation of the results of 2 much-anticipated, phase III trials of interleukin-2, ESPRIT (Evaluation of Subcutaneous Proleukin in a Randomized International Trial) and SILCAAT (Subcutaneous, Recombinant Human Interleukin-2 in HIV-Infected Patients With Low CD4+ Counts Receiving Active Antiretroviral Therapy).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
